Inherited alterations of TGF beta signaling components in Appalachian cervical cancers.
Adult
Aged
Alleles
Female
Gene-Environment Interaction
Humans
Kentucky
/ epidemiology
Logistic Models
Middle Aged
NAD(P)H Dehydrogenase (Quinone)
/ genetics
Ohio
/ epidemiology
Receptor, Transforming Growth Factor-beta Type I
/ genetics
Risk Factors
Signal Transduction
Transforming Growth Factor beta1
/ genetics
Uterine Cervical Neoplasms
/ epidemiology
West Virginia
/ epidemiology
Young Adult
Appalachia
Cervical cancer
Genetic association
Gene–environment interaction
Polymorphic allele
Journal
Cancer causes & control : CCC
ISSN: 1573-7225
Titre abrégé: Cancer Causes Control
Pays: Netherlands
ID NLM: 9100846
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
07
11
2018
accepted:
15
08
2019
pubmed:
23
8
2019
medline:
12
11
2019
entrez:
23
8
2019
Statut:
ppublish
Résumé
This study examined targeted genomic variants of transforming growth factor beta (TGFB) signaling in Appalachian women. Appalachian women with cervical cancer were compared to healthy Appalachian counterparts to determine whether these polymorphic alleles were over-represented within this high-risk cancer population, and whether lifestyle or environmental factors modified the aggregate genetic risk in these Appalachian women. Appalachian women's survey data and blood samples from the Community Awareness, Resources, and Education (CARE) CARE I and CARE II studies (n = 163 invasive cervical cancer cases, 842 controls) were used to assess gene-environment interactions and cancer risk. Polymorphic allele frequencies and socio-behavioral demographic measurements were compared using t tests and χ Several alleles demonstrated significant interaction with smoking (TP53 rs1042522, TGFB1 rs1800469), alcohol consumption (NQO1 rs1800566), and sexual intercourse before the age of 18 (TGFBR1 rs11466445, TGFBR1 rs7034462, TGFBR1 rs11568785). Interestingly, we noted a significant interaction between "Appalachian self-identity" variables and NQO1 rs1800566. Multivariable logistic regression of cancer status in an over-dominant TGFB1 rs1800469/TGFBR1 rs11568785 model demonstrated a 3.03-fold reduction in cervical cancer odds. Similar decreased odds (2.78-fold) were observed in an over-dominant TGFB1 rs1800469/TGFBR1 rs7034462 model in subjects who had no sexual intercourse before age 18. This study reports novel associations between common low-penetrance alleles in the TGFB signaling cascade and modified risk of cervical cancer in Appalachian women. Furthermore, our unexpected findings associating Appalachian identity and NQO1 rs1800566 suggests that the complex environmental exposures that contribute to Appalachian self-identity in Appalachian cervical cancer patients represent an emerging avenue of scientific exploration.
Identifiants
pubmed: 31435875
doi: 10.1007/s10552-019-01221-y
pii: 10.1007/s10552-019-01221-y
pmc: PMC6768402
mid: NIHMS1537962
doi:
Substances chimiques
TGFB1 protein, human
0
Transforming Growth Factor beta1
0
NAD(P)H Dehydrogenase (Quinone)
EC 1.6.5.2
NQO1 protein, human
EC 1.6.5.2
Receptor, Transforming Growth Factor-beta Type I
EC 2.7.11.30
TGFBR1 protein, human
EC 2.7.11.30
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1087-1100Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001070
Pays : United States
Organisme : NIH HHS
ID : UL1TR001070
Pays : United States
Organisme : NCI NIH HHS
ID : P50CA105632
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA105632
Pays : United States
Organisme : NCI NIH HHS
ID : P30CA016058-42S2
Pays : United States
Organisme : NCI NIH HHS
ID : K01 CA207599
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016058
Pays : United States
Références
Diagn Pathol. 2014 May 29;9:100
pubmed: 24884893
Lancet Oncol. 2009 Aug;10(8):772-84
pubmed: 19625214
Eur J Cancer. 2010 Jan;46(2):405-11
pubmed: 19819687
Brief Funct Genomics. 2014 Sep;13(5):353-61
pubmed: 25005607
Cancer Prev Res (Phila). 2014 Jul;7(7):639-47
pubmed: 24806664
Cancers (Basel). 2014 May 14;6(2):1138-56
pubmed: 24830349
Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3099-104
pubmed: 11867746
Environ Mol Mutagen. 2013 Aug;54(7):480-99
pubmed: 23681765
Cancer Res. 2014 Dec 1;74(23):6833-44
pubmed: 25273091
Oncotarget. 2016 Oct 25;7(43):69097-69110
pubmed: 27533245
Int J Environ Res Public Health. 2014 Dec 11;11(12):12866-95
pubmed: 25514145
PLoS One. 2015 Jan 20;10(1):e0116500
pubmed: 25602258
Cancer Treat Rev. 2016 Jan;42:30-40
pubmed: 26643553
Environ Health Perspect. 1998 Jul;106(7):365-8
pubmed: 9637792
JAMA. 2005 Oct 5;294(13):1634-46
pubmed: 16204663
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Thorax. 2014 Sep;69(9):876-8
pubmed: 24906490
Sci Rep. 2015 Aug 20;5:13300
pubmed: 26289323
Prim Care. 2019 Mar;46(1):117-134
pubmed: 30704652
Breast Cancer Res Treat. 2013 Sep;141(2):287-97
pubmed: 24036662
Cancer Causes Control. 2018 Mar;29(3):371-377
pubmed: 29423759
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt E):1-538
pubmed: 23193840
Int J Gynecol Cancer. 2017 Nov;27(9):1949-1956
pubmed: 28906311
Prev Chronic Dis. 2006 Oct;3(4):A127
pubmed: 16978502
Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13125-30
pubmed: 12232053
Int J Gynaecol Obstet. 2004 Jun;85(3):301-8
pubmed: 15145278
PLoS One. 2012;7(1):e30566
pubmed: 22272361
Br J Cancer. 2004 Feb 23;90(4):747-51
pubmed: 14970847
Front Genet. 2017 Nov 03;8:169
pubmed: 29163637
Trans Am Clin Climatol Assoc. 2014;125:300-12
pubmed: 25125747
Cytokine. 2015 Oct;75(2):344-8
pubmed: 26048435
Int J Environ Res Public Health. 2015 Dec 22;13(1):ijerph13010013
pubmed: 26703702
Eur Cytokine Netw. 2016 Nov 1;27(4):81-89
pubmed: 28396298
BMB Rep. 2015 Nov;48(11):609-17
pubmed: 26424559
Semin Oncol Nurs. 2019 Apr;35(2):166-174
pubmed: 30878194
Am J Respir Crit Care Med. 2004 Jan 15;169(2):214-9
pubmed: 14597484
Oncol Res. 2009;18(1):41-5
pubmed: 19911703
Int J Environ Res Public Health. 2014 Oct 10;11(10):10419-43
pubmed: 25310540
Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):755-61
pubmed: 20200430
Nature. 1992 Jul 2;358(6381):15-6
pubmed: 1614522
Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):472-475
pubmed: 28325736
Hum Mol Genet. 2007 Dec 15;16(24):3128-35
pubmed: 17890272
PLoS One. 2013 Aug 30;8(8):e74276
pubmed: 24023700
Prev Chronic Dis. 2006 Oct;3(4):A113
pubmed: 16978488
ISRN Obstet Gynecol. 2011;2011:847684
pubmed: 21785734
Cancer Causes Control. 2003 Nov;14(9):805-14
pubmed: 14682438
Front Microbiol. 2018 Nov 28;9:2896
pubmed: 30546351
Genet Mol Res. 2015 Jul 27;14(3):8147-60
pubmed: 26345741
J Clin Oncol. 2005 Oct 20;23(30):7743-4; author reply 7744-6
pubmed: 16234535
Nat Rev Genet. 2012 Jan 18;13(2):135-45
pubmed: 22251874
PLoS One. 2016 May 12;11(5):e0155270
pubmed: 27171242
J Rural Health. 2005 Winter;21(1):39-47
pubmed: 15667008
Medicine (Baltimore). 2018 Nov;97(46):e13061
pubmed: 30431576
Cytokine. 2015 Dec;76(2):382-390
pubmed: 26343835
Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):250-8
pubmed: 26819264
Cancer Treat Res. 2010;155:85-103
pubmed: 20517689
Oncol Lett. 2017 Jul;14(1):733-736
pubmed: 28693227
Nat Rev Cancer. 2013 Nov;13(11):788-99
pubmed: 24132110
Hum Mol Genet. 1999 Jan;8(1):93-7
pubmed: 9887336
Int J Cancer. 2007 Mar 15;120(6):1330-5
pubmed: 17187359
Int J Cancer. 2013 Mar 1;132(5):1133-45
pubmed: 22752881